Literature DB >> 9164470

A xenograft line of human teratocarcinoma established by serial transplantation in severe combined immunodeficient (SCID) mice.

Y Abe1, Y Oshika, Y Ohnishi, R Suto, T Tokunaga, H Yamazaki, H Kijima, N Hiraoka, Y Ueyama, N Tamaoki, M Nakamura.   

Abstract

We established a xenograft line of human teratocarcinoma (TC-1) and characterized the pluripotency of differentiation of the neoplastic cells. A teratocarcinoma specimen obtained from a primary mediastinal lesion (22-year-old male patient) was inoculated subcutaneously into severe combined immunodeficient (SCID) mice. The carcinoma formed tumors in the mice. We established a xenograft line by serial passage of the tumor in vivo. The primary tumor was composed of papillary and pseudoglandular nests of highly atypical epithelial cells with foci of glomeruloid structures. The metastatic cells showed apparent production of mucin and differentiation to striated muscle. The xenograft line TC-1 retained the basic histopathological features seen in the primary and metastatic cells. The xenograft line showed focal differentiation to cartilage through serial passages. Immunohistochemical studies with anti-alpha-fetoprotein (AFP) demonstrated positive immunoreactivity on the TC-1 cells. Serum AFP levels were also elevated in the TC-1-bearing SCID mice. The human teratocarcinoma xenograft line TC-1 will be useful for studying the differentiation mechanism in human totipotent stem cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164470     DOI: 10.1111/j.1699-0463.1997.tb00570.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

Review 1.  Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.

Authors:  James A Heslop; Thomas G Hammond; Ilaria Santeramo; Agnès Tort Piella; Isabel Hopp; Jing Zhou; Roua Baty; Enrique I Graziano; Bernabé Proto Marco; Alexis Caron; Patrik Sköld; Peter W Andrews; Melissa A Baxter; David C Hay; Junnat Hamdam; Michaela E Sharpe; Sara Patel; David R Jones; Jens Reinhardt; Erik H J Danen; Uri Ben-David; Glyn Stacey; Petter Björquist; Jacqueline Piner; John Mills; Cliff Rowe; Giovanni Pellegrini; Swaminathan Sethu; Daniel J Antoine; Michael J Cross; Patricia Murray; Dominic P Williams; Neil R Kitteringham; Chris E P Goldring; B Kevin Park
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.